

CURRICULUM VITAE WITH TRACK RECORD – TARJE O. HALVORSEN

ROLE IN PROJECT

Project manager ☐

Work Package Leader ☐

Project participant ☒

PERSONAL INFORMATION

Family name, First name: Halvorsen, Tarje Onsøien

Date of birth: 07.09.1976

Sex: Male

Nationality: Norwegian

Researcher unique identifier (ORCID: 0000-0002-1181-921X)

URL for personal web site: <https://www.ntnu.edu/employees/tarje.halvorsen>

EDUCATION

- 2019 Specialist in oncology
St. Olavs hospital, Norway
- 2017 PhD: «Thoracic radiotherapy in limited disease small cell lung cancer»
Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Norway
- 2003 Cand. Med.
Faculty of Medicine, University of Oslo, Norway

CURRENT AND PREVIOUS POSITIONS

- 2019- Associate professor
Department of Molecular and Clinical Medicine, Norwegian University of Science and Technology (NTNU), Norway
- 2018- Postdoctoral research fellow
Department of Molecular and Clinical Medicine, Norwegian University of Science and Technology (NTNU), Norway
- 2010- Consultant in Medical Oncology and Radiotherapy
Department of Oncology, St. Olavs hospital, Norway
- 2017-2018 Resident
Department of Internal Medicine, St. Olavs hospital, Norway
- 2012-2016 PhD student
Department of Molecular and Clinical Medicine, Norwegian University of Science and Technology (NTNU), Norway
- 2006-2010 Resident
Department of Oncology, St. Olavs hospital, Norway
- 2005-2006 General practitioner (GP),
Vestnes, Møre and Romsdal
- 2004-2005 Intern in general practice
Vestnes, Møre and Romsdal
- 2003-2004 Intern in internal medicine and surgery
Molde Hospital, Møre and Romsdal

FELLOWSHIPS AND AWARDS

- 2022 Publication of the year award
St. Olavs hospital, Norway
- 2021 Publication of the year award
Department of Molecular and Clinical Medicine, Norwegian University of Science and Technology (NTNU), Norway

PROJECT MANAGEMENT EXPERIENCE

Involved in the daily running of all clinical trials on lung cancer at the Department of Oncology, St. Olavs hospital. Projects with first-hand responsibilities:

- 2023- A randomized phase II, open-label, multicenter study investigating efficacy and safety

- of anti-PD1/PD-L1 treatment +/- UVI vaccination as first line treatment in patients with inoperable advanced of metastatic non-small cell lung cancer (the LUNGVAC-study), local investigator, sponsored by Vestre Viken HF
- 2023- Combinatory immunotherapy-2 (COM-IT-2) A phase 2 randomised open two-arm study to assess the tolerability and efficacy of immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer, local investigator, sponsored by Oslo University Hospital
- 2021- A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8), national investigator, sponsored by Astra Zeneca
- 2019- A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small-cell lung cancer (ACHILES), funded by the Liaison Committee for Education, Research and Innovation in Central Norway, sponsored by the Norwegian University of Science and Technology (NTNU), Norway

SUPERVISION OF GRADUATE STUDENTS AND RESEARCH FELLOWS

- 2016- Main supervisor of 3 PhD students, co-supervisor of 2 PhD student, supervisor of 6 medical students, Department of Molecular and Clinical Medicine, Norwegian University of Science and Technology (NTNU), Norway

TEACHING ACTIVITIES

- 2024- Lecturer – Statistics and communication of risk at national specialist course in oncology, Norwegian University of Science and Technology (NTNU) / The Norwegian Medical Association
- 2021- Lecturer – Long-term effects from lung cancer treatment, St. Olavs hospital
- 2021- Supervisor – Problem-based learning MD4030, Norwegian University of Science and Technology (NTNU)
- 2021- Lecturer – Treatment of lung cancer at national specialist course in oncology, University of Oslo / The Norwegian Medical Association
- 2019- Lecturer – Clinical training in oncology for medical students (MD4030), Norwegian University of Science and Technology (NTNU)
- 2018- Lecturer – Lung cancer for medical students (lung cancer seminar), Norwegian University of Science and Technology (NTNU)
- 2018- Lecturer – Clinical research for medical physicists, Norwegian University of Science and Technology (NTNU)
- 2018- Lecturer – Lung cancer for radiography students, Norwegian University of Science and Technology (NTNU)
- 2018- Lecturer – Targeted therapy for master students in molecular biology, Norwegian University of Science and Technology (NTNU)
- 2018- Lecturer – Radiotherapy of lung cancer for specialist candidates in internal medicine, Norwegian University of Science and Technology (NTNU) / The Norwegian Medical Association
- 2014- Instructor – Communication skills for medical students (“breaking bad news”), Norwegian University of Science and Technology (NTNU)

INSTITUTIONAL RESPONSIBILITIES

- 2019- Examiner at MD graduation and master theses and opponent at one PhD dissertation

COMMISSIONS OF TRUST

- 2019- Reviewer, Acta Oncologica, print ISSN: 0284-186X, online ISSN: 1651-226X
- 2017- Reviewer, Radiation Oncology, ISSN: 1748-717X

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

- 2021- Member of the Norwegian Lung Cancer Study Group (NLCCG)
- 2020- Member of National group of experts in lung cancer research

TRACK RECORD

1. **Total number of publications**

23 publications last 10 years

24 publications in total

2. **Relevant publications for this specific project – last 10 years**

1. Grønberg, B. H., Killingberg, K. T., Fløtten, Ø., Brustugun, O. T., Hornslien, K., Madebo, T., Langer, S. W., Schytte, T., Nyman, J., Risum, S. & **Halvorsen, T. O. (2021)**. High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. *The Lancet Oncology*, 22(3), 321-331 (**85 citations**).
2. Grønberg, B. H., **Halvorsen, T. O.**, Fløtten, Ø., Brustugun, O. T., Brunsvig, P. F., Aasebø, U., Bremnes, R. M., Tollåli, T., Hornslien, K., & Aksnessæther, B. Y. (2016). Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. *Acta Oncologica*, 55(5), 591-597. (**75 citations**)
3. **Halvorsen, T. O.**, Sundstrøm, S., Fløtten, Ø., Brustugun, O. T., Brunsvig, P., Aasebø, U., Bremnes, R. M., Kaasa, S., & Grønberg, B. H. (2016). Comorbidity and outcomes of concurrent chemo-and radiotherapy in limited disease small cell lung cancer. *Acta Oncologica*, 55(11), 1349-1354. (**22 citations**)
4. **Halvorsen, T. O.**, Herje, M., Levin, N., Bremnes, R. M., Brustugun, O. T., Fløtten, Ø., Kaasa, S., Sundstrøm, S., & Grønberg, B. H. (2016). Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer. *Lung Cancer*, 102, 9-14. (**15 citations**)
5. **Halvorsen, T. O.**, Stokke, K., Killingberg, K. T., Raj, S. X., Sørhaug, S., Brustugun, O. T., Fløtten, Ø., Helbekkmo, N., Hornslien, K., & Madebo, T. (2020). Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC. *Acta Oncologica*, 59(9), 1051-1057. (**6 citations**)
6. Graabak, G., Grønberg, B. H., Sandvei, M. S., Nilssen, Y., & **Halvorsen, T. O. (2022)**. Thoracic Radiotherapy in Limited-Stage SCLC—a Population-Based Study of Patterns of Care in Norway From 2000 Until 2018. *JTO Clinical and Research Reports*, 3(2), 100270. (**5 citations**)
7. Horndalsveen, H., Alver, T. N., Dalsgaard, A. M., Rogg, L. V., Helbekkmo, N., Grønberg, B. H., **Halvorsen, T. O.**, Ramberg, C., Haakensen, V. D., & Öjlert, Å. K. (2023). Atezolizumab and stereotactic body radiotherapy in patients with advanced non-small cell lung cancer: safety, clinical activity and ctDNA responses—the ComIT-1 trial. *Molecular Oncology*, 17(3), 487-498. (**2 citations**)
8. Killingberg, K. T., Grønberg, B. H., Slaaen, M., Kirkevold, Ø., & **Halvorsen, T. O. (2023)**. Treatment outcomes of older participants in a randomized trial comparing two schedules of twice-daily thoracic radiotherapy in limited-stage SCLC. *Journal of Thoracic Oncology*, 18(6), 803-812. (**1 citation**)
9. Killingberg, K. T., **Halvorsen, T. O.**, Fløtten, Ø., Brustugun, O. T., Langer, S. W., Nyman, J., Hornslien, K., Madebo, T., Schytte, T., & Risum, S. (2022). Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. *Lung Cancer*, 166, 49-57. (**1 citation**)
10. Levin, N., Killingberg, K. T., **Halvorsen, T. O.**, Danielsen, S., & Grønberg, B. H. (2024). Evaluation of radiotherapy treatment plans in a randomized phase II trial comparing two schedules of twice-daily thoracic radiotherapy in limited stage small-cell lung cancer. *International Journal of Radiation Oncology* Biology* Physics*.